PRAX (Praxis Corp) Rasio rega marang prakiraan pendapatan
The development of unique targeted epilepsy drugs allows Praxis Precision Medicines (PRAX) to command premium pricing. The company's expected P/S ratio confirms market expectations, with the latest mark standing at 1210.80. Stable management is precisely executing R&D plans, although geopolitical tensions and patent complexities could hinder global expansion and raw material logistics.
Rincian analitis perusahaan Praxis Precision Medicines
- rega pasar lan target rega analis:
- indikator valuasi pasar bisnis:
- indikator nilai buku ekuitas:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal Praxis Precision Medicines|PRAX - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Praxis Precision Medicines Inc|PRAX - Gunggung kewajiban utang perusahaan|Utang-utang marang kapitalisasi buku Praxis Medicines|PRAX - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Praxis Precision Medicines|Likuiditas cepet praxismedicines.com
- rincian asil keuangan lan kelipatan valuasi:
PRAX - Bathi perusahaan|Bathi mangsa ngarep Praxis Precision Medicines|PRAX - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep praxismedicines.com|PRAX - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Praxis Corp|PRAX - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Praxis Precision Medicines|PRAX - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan praxismedicines.com|PRAX - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Praxis Precision Medicines
- rincian pendapatan lan dodolan:
Analisis komprehensif perusahaan:Praxis Corp PRAX
Portfolio managers evaluate the operating model of Praxis Precision Medicines (PRAX) through the lens of future cash flows. This indicator measures the market value of one dollar of expected revenue, neutralizing the time lag between quarterly reports. By analyzing the forward P/S ratio, investors can see the current overvaluation of the potential for CNS therapies and genetic developments. The stability of this metric confirms the fundamental resilience of the company's scientific foundation in treating psychoses.
Analisis perusahaan pesaing
Multiplikator Forward P/S BIIB (Biogen Idec)|Rasio kapitalisasi marang dodolan sing dikarepake Neurocrine Corp (NBIX)|RGC: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AXSM (Axsome Therapeutics)|ACAD: Multiplikator Forward P/S|Xenon Pharmaceuticals Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Viking Pharma|SUPN: Rega forward marang dodolan|Multiplikator Forward P/S CPRX|Multiplikator Forward P/S denalitherapeutics.com (DNLI)|Multiplikator Forward P/S HRMY (Harmony Biosciences Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Biohaven (BHVN)|Amylyx Corp - Multiplikator Forward P/S|TRVI - Multiplikator Forward P/S|AVXL: Multiplikator Forward P/S|CBLL (ceribell.com) - Rasio rega marang prakiraan pendapatan|PRTA (Prothena Corporation) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan alector.com (ALEC)|Rasio rega marang prakiraan pendapatan Annexon, Inc. (ANNX)|OMER - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S NGNE (Neurogene Inc)|AC Immune (ACIU) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Voyager Therapeutics Inc - Multiplikator Forward P/S|Neumora (NMRA) - Multiplikator forward rega marang pendapatan|SCLX: Multiplikator Forward P/S|TVGN - Rasio kapitalisasi marang dodolan sing dikarepake|ACOG (Alpha Cognition Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan cogrx.com (CGTX)|Rasio rega marang prakiraan pendapatan Inhibikase Therapeutics Inc (IKT)|Rasio kapitalisasi marang dodolan sing dikarepake Cassava Sciences|Multiplikator Forward P/S ASRT (Assertio Holdings)|COYA - Multiplikator forward rega marang pendapatan|vistagen.com - Multiplikator Forward P/S|OVID: Rasio rega marang prakiraan pendapatan|Acumen Pharmaceuticals, Inc (ABOS) - Rasio rega marang prakiraan pendapatan|CervoMed Inc - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Alterity Therapeutics Limited|clene.com (CLNN) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan PEPG (PepGen Inc)|Multiplikator Forward P/S jupiterneurosciences.com (JUNS)|Rasio rega marang prakiraan pendapatan Relmada Therapeutics, Inc. RLMD|ANVS: Kapitalisasi marang prakiraan pendapatan|Grace Tx - Multiplikator Forward P/S|AIFF (Firefly Neuroscience Inc) - Kapitalisasi marang prakiraan pendapatan|KLTO: Multiplikator Forward P/S|NeuroSense Therapeutics, Ltd. (NRSN) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Reviva Pharmaceuticals, Inc.|Multiplikator forward rega marang pendapatan metaviatx.com (MTVA)|Multiplikator Forward P/S NRXS|HSDT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Passage Bio, Inc. - Multiplikator forward rega marang pendapatan|bionomics.com.au (NEUP) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Minerva - Multiplikator Forward P/S|Rega forward marang dodolan ATHA (Athira Pharma Inc)|ADXN: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ALZN|CYCN (Cyclerion Therapeutics Inc.) - Multiplikator Forward P/S|PTIX (Protagenic Therapeutics) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S KTTA|Rasio kapitalisasi marang dodolan sing dikarepake Cortigent|Multiplikator Forward P/S ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Rasio rega marang prakiraan pendapatan|Cara Therapeutics Inc. - Multiplikator Forward P/S|Chromocell Therapeutics (CHRO) - Multiplikator forward rega marang pendapatan|ELYM: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Multiplikator Forward P/S|Marinus - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S NKGN|NRBO (NeuroBo Pharmaceuticals) - Rega forward marang dodolan|Multiplikator Forward P/S SAGE (Sage Therapeutics Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Synaptogenix Inc. (SNPX)|TRVN - Rasio rega marang prakiraan pendapatan|vigilneuro.com (VIGL) - Multiplikator forward rega marang pendapatan|WENA: Multiplikator Forward P/S|Cerevel Therapeutics, Inc. (CERE) - Multiplikator Forward P/S
